All Blogs
Nov 06, 2023
Coherus and Junshi’s Loqtorzi: First-ever Chinese PD-1 Inhibitor and Nasopharyngeal Carcinoma Treatment
On 27 October 2023, Coherus BioSciences and Shanghai Junshi Biosciences received FDA approval for Loqtorzi (toripalimab), marking a significant milestone as the first-ever sanctioned treatment for nasopharyngeal carcinoma. The medication has gained approval for use alongside cisplatin and gemcitabine as an initial ...
Read More...
Nov 03, 2023
Emerging Therapies for Niemann-Pick Disease Type C Treatment: The Road to Progress
Niemann-Pick disease type C (NPC) is a rare genetic disorder caused by mutations in cholesterol trafficking proteins. There are two main types, with Type C1 being the most prevalent, accounting for around 95% of cases. While specific epidemiological data on NPC is limited, estimates suggest a prevalence of approxim...
Read More...
Nov 02, 2023
Laborie Medical Acquired Urotronic; Sirtex’s LAVA Liquid Embolic System; Paige’s Cancer Detection in Breast Lymph Nodes; FDA Clearance to Neurovalens’s Non-Invasive Insomnia-Treating Device; Recor Medical’s Renal Denervation System; Pulsecare Medical’s nsPFA Clinical Trial Short-term Follow-up Results
Neurovalens Received US FDA Clearance for Non-Invasive Insomnia-Treating Device On October 30, 2023, Belfast, Northern Ireland-based Neurovalens announced the US Food and Drug Administration clearance for its Modius Sleep device meant for treating chronic insomnia. Modius has been designed to deli...
Read More...
Nov 01, 2023
Revolutionizing Drug Discovery and Beyond: The Power of Molecular Modeling
Molecular modeling, a revolutionary branch of science that seeks to understand and manipulate the intricate world of molecules at the atomic and molecular levels, has seen a remarkable transformation in recent years, owing to the growth in technology. The union of computational science, chemistry, and biology has g...
Read More...
Oct 31, 2023
Phase III RUBY Trial of Jemperli Plus Chemotherapy Updates; FDA Approves Roche’s Vabysmo for RVO; FDA Grants Priority Review to Tovorafenib Low-Grade Glioma; FDA Approves Lilly’s Omvoh; FDA Approves Toripalimab for Nasopharyngeal Carcinoma; FDA Fast Track Designation to ONCT-534 R/R mCRPC
FDA Granted Fast Track Designation to Oncternal Therapeutics’s ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer On Oct. 26, 2023, Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting andr...
Read More...
Oct 30, 2023
Rare but Real: Unraveling the Different Types of Bone Sarcoma
Bone sarcoma is a rare and aggressive form of cancer that develops in bone tissue. The likelihood of a person being diagnosed with primary bone sarcoma and their recovery prospects depend on various unique factors. In 2023, it is expected that 4,000 individuals across all age groups in the United States will receiv...
Read More...
Oct 27, 2023
AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure
Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The...
Read More...
Oct 26, 2023
Cardio Flow’s FreedomFlow Orbital Atherectomy Peripheral Platform; Medtronic’s Aurora EV- ICD System to Treat Arrhythmias; GE Healthcare and Novo Nordisk Announces Collaboration; Olympus’s EVIS X1 Endoscopy System; Medtronic’s Evolut TAVR Platform Outperformed Surgery with Sustained Valve Performance; Abbott’s Minimally Invasive Devices for People with Leaky Heart Valves
Olympus Announced Market Launch of EVIS X1™ Endoscopy System On October 19, 2023, Olympus Corporation, a global medical technology company announced the market launch of its next-generation EVIS X1™ endoscopy system. The GIF-1100 gastrointestinal videoscope indicated for use in the upper digestive tract, and ...
Read More...
Oct 25, 2023
Charting the Growth of the Insulin Pens Market Amidst Rising Demand
The evolution of technology has been a driving force behind the remarkable growth of the Insulin Pens market. Insulin Pens, from their inception as relatively basic delivery devices, have undergone a substantial transformation, becoming highly advanced and user-friendly tools. In the early stages, these pens requir...
Read More...
Oct 24, 2023
FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1
UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...
Read More...